Introduction
The tumor suppressor protein p53 plays an important role in preventing cancer by inducing cell-cycle arrest or apoptosis in response to diverse stress signals, such as DNA damage or oncogene activation (Vousden and Lu, 2002) . p53 is regulated by Mdm2, which degrades p53 in an ubiquitin-dependent manner (Vousden and Lu, 2002) . The Mdm2 binding domain overlaps with the transcriptional activation domain of p53, so that Mdm2 inhibits the transcriptional activity of p53 as well as targeting it for degradation (Momand et al., 1992) . For these reasons, inhibition of the p53-Mdm2 binding provides an attractive strategy for activating p53 in tumors harboring the wild-type p53 gene.
Nutlin-3, a selective small-molecule inhibitor of the p53-Mdm2 interaction, activates the p53 pathway in vitro and in vivo, leading to cell-cycle arrest and/or apoptosis in various cancer cells with wild-type p53 including neuroblastoma (Van Maerken et al., 2006) , retinoblastoma (Laurie et al., 2006) , osteosarcoma (Vassilev et al., 2004) and leukemia (Stuhmer et al., 2005; Coll-Mulet et al., 2006) . In contrast, the response of normal cells, such as wild-type fibroblasts, to Nutlin-3 is largely limited to a reversible growth arrest (Vassilev et al., 2004) . Furthermore, it has been reported that, although Nutlin-3 induces cell-cycle arrest in most cancer cells with wild-type p53, it induces apoptosis only in cancer cells such as human osteosarcoma SJSA-1 cells and MHM cells that harbor mdm2 amplification (Tovar et al., 2006) . Recently, several studies suggest a key role of MdmX, an Mdm2 homolog that inhibits p53 transactivation, in the sensitivity and apoptotic response to Nutlin-3 in certain cancer cell lines (Laurie et al., 2006; Patton et al., 2006; Wade et al., 2006) . However, previous reports and our study here show that Nutlin-3 also induces apoptosis in many cancer cell lines that do not possess either mdm2 amplification or MdmX overexpression (Tovar et al., 2006; Wade et al., 2006;  in this study) suggests that additional factors sensitize cancer cells to Nutlin-3-induced apoptosis.
E2F transcription factors consist of heterodimers between E2F (E2F-1B8) and DP (DP-1B2), and are involved in the G1/S phase transition, differentiation and apoptosis (Dyson 1998; Stanelle and Pu¨tzer, 2006) . Among these, E2F-1 can induce p53-dependent or -independent apoptosis through transcriptional induction of various target genes, including Arf, Apaf-1, caspases, Puma, Noxa and p73, or through inactivation of anti-apoptotic survival factors, such as NF-kB (Bates et al., 1998; Holmberg et al., 1998; Stanelle and Pu¨tzer, 2006) . Notably, p73, a homologue of p53, is capable of inducing apoptosis by transcriptional activation of its target genes. These genes overlap with, but are not identical to p53-responsive genes. Furthermore, p73 has been shown to be required for E2F-1-induced apoptosis (Irwin et al., 2000; Stiewe and Pu¨tzer, 2000) .
Here, we identify subsets of tumor cell lines that undergo apoptosis after treatment with Nutlin-3. In these cell lines, neither the status of Mdm2 nor MdmX correlates well with their apoptotic response to Nutlin-3.
In contrast, we demonstrate that high transcriptional activity of E2F determines the apoptotic response to Nutlin-3 in p53 wild-type cancer cell lines and we provide a potential molecular mechanism. We demonstrate that protein levels of p73 are constitutively induced by Nutlin-3 in wild-type p53 cell lines with mutated Rb, whereas depletion of E2F-1 reduces its transcriptional target p73 and suppresses Nutlin-3-induced apoptosis. Furthermore, depletion of p73 suppresses Nutlin-3-induced apoptosis, suggesting that high transcriptional activity of E2F, especially E2F-1, determines the apoptotic response to Nutlin-3 in a p73-dependent manner, especially in Rb mutated cells. Taken together, our study indicates that high transcriptional activity of E2F-1 in cancer cells could be a key determinant of the apoptotic response to Nutlin-3 and cells with high E2F-1 activity would be preferred targets for Nutlin-3 treatment.
Results
Identification of subsets of tumor cell lines that are highly sensitive to Nutlin-3 in vitro and in vivo Nutlin-3 induces cell-cycle arrest in most cancer cells with wild-type p53, but only induces apoptosis in certain cancer cells (Tovar et al., 2006) . To identify subsets of highly sensitive tumor cell lines that undergo apoptosis after treatment with Nutlin-3, we randomly selected 13 cancer cell lines with wild-type p53 including 5 cell lines from leukemia and 8 cell lines from solid tumors. Consistent with previous reports, Nutlin-3 efficiently inhibited growth of all cancer cell lines we evaluated (data not shown), however, Nutlin-3 markedly increased Caspase-3/7 activity only in specific cancer cell lines ( Figure 1a ). The proportion of Annexin V positive cells was also markedly increased by Nultin-3 in those cells showing a high Caspase-3/7 activity, but not in other cells (Supplementary Figure 1A) . In agreement with previous reports that leukemia cells are sensitive to p53-induced apoptosis (Kojima et al., 2005; Stuhmer et al., 2005; Secchiero et al., 2006) , all leukemia cell lines that we tested underwent apoptosis ( Figure 1a) . Next, we investigated whether the apoptotic response induced by Nutlin-3 correlated with its antitumor response. Nutlin-3 completely suppressed tumor growth of xenografted SJSA-1 osteosarcoma and MV4;11 leukemia cell lines (Figure 1b) , which also caused apoptotic response to Nutlin-3 in vitro (Figure 1a) . In contrast, Nutlin-3 partially suppressed tumor growth of xenografts of HCT116 or A2780 (Figure 1b) , which did not undergo apoptosis after treatment with Nutlin-3 (Figure 1a ), suggesting that in vitro apoptotic response to Nutlin-3 correlates to in vivo antitumor response.
The status of Mdm2 and MdmX does not correlate with the apoptotic response to Nutlin-3 Apoptosis induced by p53 also depends on the level of p53 activation (Vousden, 2000) . To determine whether the difference in Nutlin-3-mediated apoptosis between the high sensitivity and the low sensitivity groups of cell lines was due to differences in the transactivation ability of p53, we determined the expression levels of transcriptional targets of p53 upon Nutlin-3 treatment. As shown in the Figure 1c , Nutlin-3 stabilized p53 and induced p53 targets (Mdm2, p21 and Puma) to comparable levels in the highly sensitive SJSA-1 cells and the less sensitive HCT116 and U2OS cells, as determined by immunoblot analysis, indicating that apoptosis induced by Nutlin-3 does not correlate with levels of p53 activation. As mdm2 gene amplification has been reported as an indicator of an apoptotic response to Nutlin-3 (Tovar et al., 2006) , we examined protein and mRNA expression levels of Mdm2 in various tumor cell lines. Consistent with previous reports, both protein and mRNA expression levels of Mdm2 were significantly higher in SJSA-1, which showed significant apoptosis following treatment with Nutlin-3 (Figure 1d ). However, we did not observe high levels of Mdm2 in other highly sensitive cell lines, including leukemia and DU4475 cells (Figure 1d ). Furthermore, in the choriocarcinoma cell line JAR that is known to overexpress Mdm2 via mdm2 gene amplification (Chen et al., 1999 ; Figure 1d ), Nutlin-3 did not induce significant cell death ( Figure 1a ; Supplementary Figure 1A) . As previous reports indicated a key role of MdmX in the apoptotic response to Nutlin-3 (Laurie et al., 2006; Patton et al., 2006; Wade et al., 2006) , we also examined the protein levels of MdmX in these cell lines. As shown in Figure 1d , the protein levels of MdmX did not correlate with the apoptotic response to Nutlin-3. We also examined the protein levels of MdmX in these cells treated with Nutlin-3 (Wade et al., 2006) . In agreement with previous reports, we observed downregulation of MdmX in some cell lines, but not others (Supplementary Figure 1B) . Furthermore, downregulation of MdmX did not correlate well with sensitivity to Nutlin-3 (Supplementary Figure 1B ), and depletion of MdmX using small interfering RNA (siRNA) did not sensitize HCT116 cells to Nutlin-3-induced apoptosis as determined by Annexin V staining (Supplementary Figure  1C) . Taken together, these results indicate additional factors other than the status of Mdm2 and MdmX determine the susceptibility of cells to Nutlin-3-induced apoptosis.
The adenoviral oncoprotein early region 1A (E1A) converts the cytostatic effect of Nutlin-3 to a cell death . Total mRNAs were extracted and subjected to quantitative PCR analysis for mdm2 gene. Mdm2 mRNA expression levels were normalized to internal control using Gus expression levels (bottom graph). The average from three independent experiments is shown with s.d. DMSO, dimethylsulphoxide.
E2F activity modulates apoptotic response to Nutlin-3 M Kitagawa et al phenotype in a p53-dependent manner. Oncogenic signals such as the adenovirus E1A render primary cells sensitive to induction of apoptosis in a p53-dependent and independent manner by diverse stimuli, including many anticancer agents (Lowe et al., 1993; Pu¨tzer et al., 2000) . Thus, we wished to determine whether oncogenic signals sensitize cells to induction of apoptosis by Nutlin-3. It has been shown that mutations of p53 and ARF happen in a mutually exclusive manner (Nicholson et al., 2001) . Indeed, p53 wild-type tumor cell lines, which we tested in this study, possess mutated Arf except SJSA-1 and JAR. Furthermore, depletion of Arf by siRNA transfection did not affect Nutlin-3-induced apoptosis in SJSA-1 cells (Supplementary Figure 2A) , excluding the possibility that Arf might affect the apoptotic response of these cells to Nutlin-3. Therefore, for the analysis of oncogenic signals effects on Nutlin-3-induced apoptosis, we generated ArfÀ/À mouse embryonic fibroblast (MEF) cells stably expressing a panel of oncogenes, including E1A-ER, Myc-ER, Raf-AR and Akt-ER by retrovirus infection. Among this series of oncogenes, only activation of E1A by 4-HT increased Nutlin-3-induced Caspase-3/7 activity ( Figure 2b , left panel, Supplementary Figure 2B ). Consistent with this, activation of E1A by 4-HT caused a marked increase in the number of detached cells, indicating cell death in the presence of Nutlin-3, whereas Nutlin-3 alone caused growth arrest ( Figure 2a ). As the sensitivity of mouse cells to Nutlin-3 was approximately twofold lower than in human cancer cells (data not shown), we used 20 mM of Nutlin-3 in MEF cells, although we also observed a synergistic increase in apoptosis upon 10 mM of Nutlin-3 treatment together with E1A activation in ArfÀ/À MEF cells (Figure 2b ). Furthermore, activation of E1A by 4-HT together with Nutlin-3 did not show any measurable difference of apoptotic activity in E1A-ER p53À/À MEF cells (Figure 2b ), indicating that this synergistic effect on apoptosis depends on p53. Taken together, these results suggest that Nutlin-3 together with E1A induces apoptosis in a p53-dependent manner.
Inactivation of pRb increases Nutlin-3-induced apoptosis As E1A binds and inactivates pRb (Brockmann and Esche, 1995) , we wished to determine whether the suppression of pRb function induces apoptosis after treatment with Nutlin-3. To address this question, we engineered ArfÀ/À MEF cells stably expressing the E1A-ER mutants, DCR2-ER and pm124-ER, that fail to bind to pRb (Samuelson and Lowe, 1997) . Activation of DCR2-ER and pm124-ER failed to induce apoptosis by Nutlin-3 (Figure 2c ), indicating that E1A enhances Nutlin-3-induced apoptosis through inactivating pRb. To further evaluate the role of pRb in Nutlin-3-induced apoptosis, we examined the effects of pRb depletion by siRNA transfection (Figure 2d ). Depletion of pRb in ArfÀ/À MEF cells increased Caspase-3/7 activity by approximately three-to fourfold compared with Nutlin-3 treatment alone. Furthermore, depletion of pRb by siRNA transfection together with Nutlin-3 treatment increased the proportion of Annexin V positive cells in HCT116 cells, but not in HCT116 p53À/À cells ( Figure 3A ). Taken together, these results suggest that inactivation of pRb increases Nutlin-3-induced apoptosis in a p53-dependent manner.
Nutlin-3 induces apoptosis in cancer cell lines possessing high E2F transcriptional activity As depletion of pRb by siRNA transfection in the presence of Nutlin-3 synergistically induces apoptosis in HCT116 cells ( Figure 3A) , it was possible that depletion of pRb might increase the transcriptional activity of p53 after Nutlin-3 treatment. However, Nutlin-3 treatment to pRb-depleted HCT116 by siRNA transfection did not increase p53 reporter (p53RE-Luc) activity further compared to HCT116 cells transfected with control siRNA ( Figure 3B(a) ). As pRb directly binds and inactivates E2F (Dyson 1998; Stanelle and Pu¨tzer, 2006) and dysregulation of E2F could cause apoptosis (Qin et al., 1994; Shan and Lee, 1994) , we wished to determine the transcriptional activity of E2F using an E2F-responsive reporter (E2F-Luc). Nutlin-3 treatment decreased E2F reporter activity in HCT116 cells, but not in HCT116 p53À/À cells ( Figure 3B(b,d) ), indicating that Nutlin-3 suppresses E2F activity in a p53-dependent manner. In contrast, pRb depletion by siRNA transfection recovered this Nutlin-3-induced reduction of E2F reporter activity up to approximately 70% of DMSO (dimethylsulphoxide) control in HCT116 cells ( Figure 3B(b) ). Furthermore, Nutlin-3-induced protein levels of the E2F target Puma were further enhanced by pRb depletion in HCT116 cells ( Figure 3A) , raising the possibility that transcriptional activity of E2F might affect the apoptotic response of cells to Nutlin-3. To test this hypothesis, we evaluated the transcriptional activity of E2F in various cancer cells that were successfully transfected with E2F reporter plasmids. Indeed, the cell lines in the high sensitivity group, including DU4475, SJSA-1 and all leukemia cell lines, showed higher E2F transcriptional activity compared to the cell lines in the low sensitivity group ( Figure 3C ). Furthermore, although Nutlin-3 decreased E2F transcriptional activity in most of wild-type p53 tumor cells, E2F activities were substantially higher in the highly sensitive cell lines compared to the low sensitive cell lines (Supplementary Figure 3) upon Nutlin-3 treatment, suggesting that higher E2F transcriptional activity might be an indicator for the apoptotic response to Nutlin-3. Interestingly, among highly sensitive cell lines, only DU4475 cell line harbors mutated Rb. Indeed, the transcriptional activity of E2F was not decreased by Nutlin-3 in DU4475 cells (Supplementary Figure 3) , suggesting that Rb status in cancer cells might determine the E2F activity and the sensitivity to Nultin-3-induced apoptosis. To test this hypothesis, we examined apoptotic response of WERIRb-1 and Y-79 retinoblastoma cells to Nutlin-3, as most retinoblastoma cells harbor mutated Rb resulting in deregulated E2F activity and these cells possess wildtype p53. Indeed, these Rb mutated cell lines with wildtype p53 possessed high E2F transcriptional activity E2F activity modulates apoptotic response to Nutlin-3 M Kitagawa et al E2F activity modulates apoptotic response to Nutlin-3 M Kitagawa et al ( Figure 3C ) and Nutlin-3 failed to decrease E2F reporter activity in these cells (Supplementary Figure 3) . Furthermore, Nutlin-3 markedly increased Caspase-3/7 activity by more than 10-fold in these cell lines ( Figure 3D ).
E2F-1 is critical for Nutlin-3 to induce apoptosis in human cancer cells Among E2F family member (E2F-1 through 6), E2F-1 is known to be largely responsible for inducing apoptosis (Stanelle and Pu¨tzer, 2006) . Thus, we evaluated the role of E2F-1 in Nutlin-3-induced apoptosis. Transfection of two different siRNAs against E2F-1 to SJSA-1 cells downregulated E2F-1 protein levels by >90%, and decreased the amounts of cleaved Caspase-3 and Caspase-7 induced by Nutlin-3 ( Figure 4A ; left panel). Consistent with this result, depletion of E2F-1 markedly suppressed Nutlin-3-induced apoptosis, determined by Caspase-3/7 activity and the proportion of Annexin V positive cells ( Figure 4A ; right panels). To validate these observations in other cancer cell lines, we used the highly sensitive cell lines including RS4;11 and Molt-4 (leukemia), DU4475 (breast carcinoma) and Y-79 (retinoblastoma). Indeed, depletion of E2F-1 suppressed Nutlin-3 induced apoptosis in these cell lines ( Figure 4B ). Next, we tested whether depletion of E2F-1 would suppress apoptosis induced by Nutlin-3 together with depletion of pRb, as depletion of pRb by siRNA transfection together with Nutlin-3 treatment increased apoptosis in HCT116 cells ( Figure 3A) . Indeed, depletion of E2F-1 completely abrogated Nutlin-3-induced apoptosis in the pRb-depleted cells ( Figure 4C ), suggesting that activation of E2F-1 by depletion of pRb controls Nutlin-3-induced apoptosis in HCT116 cells.
p73 is important for Nutlin-3-induced apoptosis in tumor cells with mutated Rb Next, we wished to determine how high E2F activity sensitizes cells to apoptotic response induced by Nutlin-3. To address this question, we first determined the protein levels of E2F-1 in highly sensitive and low sensitive cell lines ( Figure 5A ). Consistent with E2F activity, protein levels of E2F-1 were relatively higher in highly sensitive cell lines than low sensitive cell lines ( Figure 5A ). As a previous study has shown that Nutlin-3 decreases the protein levels of E2F-1 in cells with wildtype p53, 24 h after Nutlin-3 treatment, we also observed a decrease in the protein levels of E2F-1 in several cancer cell lines including SJSA-1, HCT116 and U2OS cells ( Figure 5A ). However, treating Nutlin-3 to DU4475, Y-79 and WERI-Rb-1 cells, which harbor mutated Rb, failed to suppress the protein levels of E2F-1 ( Figure 5A ). Furthermore, when we depleted pRb in HCT116 cells by siRNA transfection, the protein levels of E2F-1 did not decrease upon Nutlin-3 treatment ( Figure 5E , lanes 4-6), suggesting that decrease in the protein levels of E2F by Nutlin-3 depends on Rb status. p53 homologue p73 is a transcriptional target of E2F-1 and is thought to be required for E2F-1-induced apoptosis (Irwin et al., 2000) . Interestingly, as protein levels of E2F-1 did not decrease upon Nutlin-3 treatment in Rb mutated cell lines including DU4475, Y-79, WERI-Rb-1 and pRb-depleted HCT116 cells, levels of p73 upon Nutlin-3 treatment were constitutively higher in these cells ( Figures 5A and E, lanes 7-9) . Thus, we asked whether p73 is a factor that mediates E2F-1-dependent apoptosis induced by Nutlin-3 in Rb mutated Y-79 and DU4475 cells. Indeed, depletion of E2F-1 in these cells decreased levels of p73 protein compared to control siRNA transfectants ( Figure 5B) . Furthermore, depletion of p73 by siRNA transfection markedly suppressed Nutlin-3-induced apoptosis to an extent that is comparable to depletion of E2F-1 ( Figure 5C ). Moreover, depletion of p73 together with pRb by siRNA transfection suppressed Nutlin-3-induced apoptosis in HCT116 cells, whereas depletion of pRb alone markedly induced apoptosis ( Figure 5F ). Consistent with the observed decrease in apoptosis in response to Nutlin-3, induction of Noxa upon Nutlin-3 treatment was suppressed by depletion of E2F-1 or p73 by siRNA transfection in Y-79 cells ( Figure 5D ). Taken together, we conclude that high transcriptional activity of E2F-1 is a critical determinant of Nutlin-3-induced apoptosis in cancer cells with wild-type p53 and that p73 is important for E2F-1-mediated apoptosis induced by Nutlin-3 especially in tumor cells with mutated Rb.
Discussion
In this report, we demonstrate that the pRb/E2F-1 pathway is a key determinant of Nutlin-3-induced apoptosis in p53 wild-type cancer cell lines. High E2F transcriptional activity correlates with the apoptotic response to Nutlin-3 in various cancer cells and we provide a potential molecular mechanism to explain this observation.
Treating cancer cells harboring wild-type p53 with Nutlin-3 generally causes growth inhibition. However, Nutlin-3 also induces apoptosis in certain cancer cells. Previous studies reported that mdm2 amplification in cancer cells, including human osteosarcoma SJSA-1 and MHM cells, may predict whether Nutlin-3 provokes apoptosis (Tovar et al., 2006) . Although we also found that Nutlin-3 induces significant apoptosis in SJSA-1 (Figure 1a, Supplementary Figure 1A) , the mRNA and protein levels of Mdm2 did not correlate well with the apoptotic response to Nutlin-3 in a panel of cancer cells that we tested in this study (Figure 1d ). For instance, in the choriocarcinoma cell line JAR, in which Mdm2 is overexpressed via mdm2 gene amplification (Chen et al., 1999;  Figure 1d ), Nutlin-3 does not induce significant apoptosis (Figure 1a; Supplementary Figure 1A) . Furthermore, although the mRNA and protein levels of Mdm2 are not high in DU4475 breast carcinoma and most leukemia cell lines including MV4;11, Molt-4 and MOLM-14, Nutlin-3 causes a significant apoptosis in these cell lines (Figures 1a and d) . It has also been proposed that the Mdm2-related protein, MdmX, plays a key role in the antiapoptotic response to Nutlin-3 E2F activity modulates apoptotic response to Nutlin-3 M Kitagawa et al ((a) or (b) ). Seventytwo hours after transfection, cells were treated with the indicated amounts of Nutlin-3 for 24 h (Molt-4, RS4;11) or 72 h (SJSA-1, DU4475 and Y-79). Caspase-3/7 activity was measured and normalized to a number of viable cells, and indicated as a fold induction compared to DMSO control with non-silencing siRNA. The average from three independent experiments is shown with s.d. For A, the percentage of Annexin V positive cells was determined (right graph) and total lysates were subjected to immunoblot analysis for indicated proteins (left panel). (C) HCT116 cells were transfected with 200 nM of non-silencing siRNA (c), 100 nM each of pRb siRNA together with non-silencing siRNA (pRb) or 100 nM each of pRb siRNA together with E2F-1 siRNA (pRb þ E2F-1). Seventy-two hours after transfection, cells were treated with 10 mM of Nutlin-3 for 48 h. Cells were harvested and total lysates were subjected to immunoblot analysis for pRb and E2F-1 (left panel). Caspase-3/7 activity was measured and normalized to a number of viable cells, and indicated as a fold induction compared to DMSO control with non-silencing siRNA (middle panel). The average of Caspase-3/7 activity from three independent experiments is shown with s.d. The percentage of Annexin V positive cells was determined (right panel). DMSO, dimethylsulphoxide; siRNA, small interfering RNA. Y-79 or DU4475 cells were transfected with 100 nM of non-silencing siRNA (con), 100 nM of E2F-1 or p73 siRNAs ((a) or (b)). Seventy-two hours after transfection, cells were treated with 5 or 10 mM of Nutlin-3 for 72 h. Cells were harvested and total lysates were subjected to immunoblot analysis for indicated proteins (B). Caspase-3/7 activity was measured and normalized to a number of viable cells, and indicated as a fold induction compared to DMSO control with non-silencing siRNA (C). The average from three independent experiments is shown with s.d. (D) Y-79 cells were transfected with 100 nM of non-silencing siRNA (control), 100 nM of E2F-1 or p73 siRNAs (a). Seventy-two hours after transfection, cells were treated with 5 or 10 mM of Nutlin-3 for 24 h. Total mRNAs were extracted and subjected to quantitative PCR analysis for noxa. The mRNA levels of noxa were normalized to internal control using GAPDH expression levels. (E and F) HCT116 cells were transfected with 200 nM of non-silencing siRNA (c), 100 nM each of pRb siRNA together with non-silencing siRNA (pRb) or 100 nM each of pRb siRNA together with p73 siRNA (pRb þ p73 (b)). Seventy-two hours after transfection, cells were treated with 10 mM of Nutlin-3 for 48 h. Cells were harvested and total lysates were subjected to immunoblot analysis for indicated proteins (E). Caspase-3/7 activity was measured and normalized to a number of viable cells, and indicated as a fold induction compared to DMSO control with non-silencing siRNA (F). The average from three independent experiments is shown with s.d. DMSO, dimethylsulphoxide; GAPDH, glyceraldehydephosphate dehydrogenase; siRNA, small interfering RNA.
E2F activity modulates apoptotic response to Nutlin-3 M Kitagawa et al (Laurie et al., 2006; Patton et al., 2006; Wade et al., 2006) . However, the levels of MdmX protein did not correlate with the apoptotic response to Nutlin-3 (Figure 1d ) either, and depletion of MdmX using siRNA did not sensitize HCT116 cells to Nutlin-3-induced apoptosis (Supplementary Figure 1C) . Taken together, we propose that Mdm2 and MdmX might contribute to the apoptotic response to Nutlin-3 in some cells, but additional factors determine this response. Here, we demonstrate that high transcriptional activity of E2F, especially E2F-1, determines apoptotic response to Nutlin-3 in p53 wild-type cancer cells. Several lines of evidences support our conclusion. First, among several oncogenes that we tested, only E1A sensitizes p53 wildtype MEF cells to Nutlin-3-induced cell death through inhibition of pRb (Figures 2b and c, Supplementary  Figure 2B) . Second, Nutlin-3 treatment alone to HCT116 cells decreases levels of E2F-1 protein and E2F reporter activity, whereas depletion of pRb by siRNA transfection together with Nutlin-3 restores E2F reporter activity and increases apoptosis in these cells (Figure 3) . Third, all cancer cells possessing high transcriptional activities of E2F, which we tested in this study, undergo significant apoptosis by treating with Nutlin-3. Finally, depletion of E2F-1 by siRNA transfection markedly suppresses Nutlin-3-induced apoptosis in various cancer cells.
It has been shown that Nutlin-3 decreases the protein levels of E2F-1 in p53 wild-type cell lines, but not in p53 mutated cell lines (Ambrosini et al., 2007) . We also observed that Nutlin-3 decrease levels of E2F-1 protein in some cell lines possessing wild-type p53. However, we show that levels of E2F-1 protein and the transcriptional activity of E2F upon Nutlin-3 treatment are maintained at high levels in those high sensitive cell lines (Figures 3B and 5A;  Supplementary Figure 3) . Furthermore, Nutlin-3 fails to decrease levels of E2F-1 protein and the transcriptional activity of E2F in p53 wild-type cancer cell lines with mutated Rb (Figure 5A; Supplementary Figure 3) . In addition, when pRb is depleted by siRNA transfection in HCT116 cells, Nutlin-3 fails to decrease levels of E2F-1 protein, suggesting that decreases in levels of E2F-1 protein by Nutlin-3 depend on Rb status ( Figure 5E ). Importantly, depletion of E2F-1 by siRNA transfection in all these cell lines markedly suppresses Nutlin-3-induced apoptosis. Taken together, we conclude that E2F-1 is an important determinant of Nutlin-3-induced apoptosis in tumor cells possessing wild-type p53.
How, then, does E2F-1 sensitize cells to Nutlin-3-induced apoptosis? E2F-1 can induce p53-dependent or -independent apoptosis through transcriptional induction of various target genes (Stanelle and Pu¨tzer, 2006) . Arf is one of the best characterized E2F-1 target genes that promote the p53-dependent apoptosis through binding to Mdm2 and inhibiting the ubiquitin-mediated p53 degradation by Mdm2 (Bates et al., 1998) . However, we demonstrated here that inactivation of pRb by E1A is sufficient to convert the cellular response to Nutlin-3 from growth arrest to apoptosis in ArfÀ/À MEFs (Figure 2) , and that depletion of pRb by siRNA transfection in HCT116 cells, which do not express Arf, sensitizes cells to Nutlin-3-induced apoptosis ( Figure 3A) . Furthermore, depletion of Arf by siRNA transfection does not affect Nutlin-3-induced apoptosis in SJSA-1 cells possessing wild-type Arf ( Supplementary Figure 2A) , suggesting that factors other than Arf sensitize cancer cells to Nutlin-3-induced apoptosis through E2F-1. In this context, p73, a homolog of p53, has been shown as a transcriptional target of E2F-1 and is thought to be required for E2F-1-induced apoptosis (Irwin et al., 2000) . Indeed, we observed highly elevated levels of p73 in the highly sensitive cell lines with mutated Rb, whereas depletion of E2F-1 by siRNA transfection decreases the protein levels of p73 ( Figure 5B ). Furthermore, as it has been shown that Nutlin-3 stabilizes p73 and induces p73-mediated apoptosis in p53À/À cells by disrupting p73-binding of Mdm2 (Lau et al., 2008) , we also observed that Nutlin-3 inhibits the ability of Mdm2 to bind p73 and stabilizes p73 in wild-type p53 cells with mutated Rb (Supplementary Figure 4) , resulting in a significant apoptotic response to Nutlin-3 ( Figure 3D ). In contrast, depletion of p73 by siRNA transfection markedly suppresses Nutlin-3-induced apoptosis in these cell lines ( Figure 5C ), suggesting that p73 is important for E2F-1-mediated apoptosis induced by Nutlin-3 in p53 wild-type cancer cells, particularly, with mutated Rb. It has been shown that Nutlin-3 inhibits the binding of pRb and Mdm2 to E2F-1 in p53 negative cells, resulting in E2F-1-mediated apoptosis through p73 activation (Ambrosini et al, 2007) . Thus, it is also possible that Nutlin-3 might disrupt the binding of pRb and Mdm2 to E2F-1 in wild-type p53 cell lines in high sensitivity group, which might increase the Nutlin-3-induced apoptosis through p73 activation. However, it is important to note that other highly sensitive cell lines including SJSA-1 cells do not show high levels of p73, suggesting that additional factors to p73 might sensitize those cells to Nutlin-3-induced apoptosis, and this warrants further study.
In conclusion, our study indicates that the transcriptional activity of E2F is an important determinant of Mdm2 antagonist-induced apoptosis. Our study also suggests that tumor cells possessing wild-type p53 with mutated Rb could be a good target for Mdm2 antagonist therapy. As 40-50% of retinoblastoma harbors mutated Rb, but wild-type p53, our study may provide a rationale to target retinoblastoma for Mdm2-antagonist therapy. Furthermore, as deregulation of E2F-1 is a common event in most human cancers, our findings suggest a mechanism basis for the selectivity of Mdm2 antagonist for cancer cells vs normal cells.
Materials and methods
Cell lines, reagents and siRNAs Cell culture, reagents and siRNA details, including oligonucleotide sequences, are in Supplementary material.
Vector construction and retrovirus infection pBabepuro/E1A-ER, DCR2-ER and pm124-ER were cloned from pCMV/E1A, pCAN/DCR2, pCAN/pm124, respectively E2F activity modulates apoptotic response to Nutlin-3 M Kitagawa et al
